Venture round

Presidio Property Trust Announces Series D Preferred Stock Cash Dividend

Retrieved on: 
Wednesday, April 3, 2024
Trust, SAN, Venture round

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: SQFT; SQFTP; SQFTW) Presidio Property Trust, Inc. (“Presidio” or the “Company”), an internally managed, diversified real estate investment trust (“REIT”), today announced that its Board of Directors has authorized, and the Company has declared, a dividend on its 9.375% Series D Cumulative Redeemable Perpetual Preferred Stock (the “Series D Preferred Stock”) for the months of April 2024, May 2024 and June 2024.

Key Points: 
  • SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: SQFT; SQFTP; SQFTW) Presidio Property Trust, Inc. (“Presidio” or the “Company”), an internally managed, diversified real estate investment trust (“REIT”), today announced that its Board of Directors has authorized, and the Company has declared, a dividend on its 9.375% Series D Cumulative Redeemable Perpetual Preferred Stock (the “Series D Preferred Stock”) for the months of April 2024, May 2024 and June 2024.
  • In accordance with the terms of the Series D Preferred Stock, the April 2024 Series D dividend will be payable in cash in the amount of $0.19531 per share on May 15, 2024, to shareholders of record of Series D Preferred Stock as of the dividend record date of April 30, 2024.
  • The May 2024 Series D dividend will be payable in cash in the amount of $0.19531 per share on June 17, 2024, to shareholders of record of Series D Preferred Stock as of the dividend record date of May 31, 2024.
  • The June 2024 Series D dividend will be payable in cash in the amount of $0.19531 per share on July 15, 2024, to shareholders of record of Series D Preferred Stock as of the dividend record date of June 28, 2024.

Safe Bulkers, Inc. Declares Quarterly Dividend on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares; 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares

Retrieved on: 
Wednesday, April 3, 2024
Series, Venture round, Transport, Life insurance

MONACO, April 03, 2024 (GLOBE NEWSWIRE) -- Safe Bulkers, Inc. (the “Company”) (NYSE: SB), an international provider of marine drybulk transportation services, announced today that the Company’s Board of Directors has declared:

Key Points: 
  • MONACO, April 03, 2024 (GLOBE NEWSWIRE) -- Safe Bulkers, Inc. (the “Company”) (NYSE: SB), an international provider of marine drybulk transportation services, announced today that the Company’s Board of Directors has declared:
    a cash dividend of $0.50 per share on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares (the “Series C Preferred Shares”) (NYSE: SB.PR.C) for the period from January 30, 2024 to April 29, 2024;
    a cash dividend of $0.50 per share on its 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares (the “Series D Preferred Shares”) (NYSE: SB.PR.D) for the period from January 30, 2024 to April 29, 2024.
  • Each dividend will be paid on April 30, 2024 to all shareholders of record as of April 18, 2024 of the Series C Preferred Shares and of the Series D Preferred Shares, respectively.
  • The declaration and payment of future dividends, if any, will always be subject to the discretion of the Board of Directors of the Company.
  • There is no guarantee that the Company’s Board of Directors will determine to issue cash dividends in the future.

Costamare Inc. Declares Quarterly Dividend on Its Preferred and Common Stock

Retrieved on: 
Tuesday, April 2, 2024
Venture round, Costamare, CMRE, Security (finance)

MONACO, April 02, 2024 (GLOBE NEWSWIRE) -- Costamare Inc. (the “Company”) (NYSE: CMRE) has declared cash dividends of US $0.476563 per share on its 7.625% Series B Cumulative Redeemable Perpetual Preferred Stock (the “Series B Preferred Stock”) (NYSE: CMRE PR B), US $0.531250 per share on its 8.50% Series C Cumulative Redeemable Perpetual Preferred Stock (the “Series C Preferred Stock”) (NYSE: CMRE PR C), US $0.546875 per share on its 8.75% Series D Cumulative Redeemable Perpetual Preferred Stock (the “Series D Preferred Stock”) (NYSE: CMRE PR D) and US $0.554688 per share on its 8.875% Series E Cumulative Redeemable Perpetual Preferred Stock (the “Series E Preferred Stock”) (NYSE: CMRE PR E).

Key Points: 
  • MONACO, April 02, 2024 (GLOBE NEWSWIRE) -- Costamare Inc. (the “Company”) (NYSE: CMRE) has declared cash dividends of US $0.476563 per share on its 7.625% Series B Cumulative Redeemable Perpetual Preferred Stock (the “Series B Preferred Stock”) (NYSE: CMRE PR B), US $0.531250 per share on its 8.50% Series C Cumulative Redeemable Perpetual Preferred Stock (the “Series C Preferred Stock”) (NYSE: CMRE PR C), US $0.546875 per share on its 8.75% Series D Cumulative Redeemable Perpetual Preferred Stock (the “Series D Preferred Stock”) (NYSE: CMRE PR D) and US $0.554688 per share on its 8.875% Series E Cumulative Redeemable Perpetual Preferred Stock (the “Series E Preferred Stock”) (NYSE: CMRE PR E).
  • The dividend for the Series B Preferred Stock, the Series C Preferred Stock, the Series D Preferred Stock and the Series E Preferred Stock is for the period from January 15, 2024, to April 14, 2024.
  • The dividend will be paid on April 15, 2024 to all holders of record as of April 12, 2024 of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock.
  • The dividend for the common stock is payable on May 6, 2024, to holders of record of common stock as of April 19, 2024.

Arbor Realty Trust Declares Preferred Stock Dividends

Retrieved on: 
Friday, March 29, 2024
Venture round, ABR

UNIONDALE, N.Y., March 29, 2024 (GLOBE NEWSWIRE) -- Arbor Realty Trust, Inc. (NYSE: ABR), today announced that its Board of Directors has declared cash dividends on the Company's Series D, Series E, and Series F cumulative redeemable preferred stock of $0.3984375, $0.390625, and $0.390625 per share, respectively.

Key Points: 
  • UNIONDALE, N.Y., March 29, 2024 (GLOBE NEWSWIRE) -- Arbor Realty Trust, Inc. (NYSE: ABR), today announced that its Board of Directors has declared cash dividends on the Company's Series D, Series E, and Series F cumulative redeemable preferred stock of $0.3984375, $0.390625, and $0.390625 per share, respectively.
  • The Series D, E, and F preferred stock dividends reflect accrued dividends from January 30, 2024 through April 29, 2024.
  • The dividends are payable on April 30, 2024 to preferred stockholders of record on April 15, 2024.

RenovoRx Announces $11.1 Million at Market Private Placement

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Pharmaceutical, Health, Oncology, LAPC, Venture round, TAMP, Pancreatic cancer, Sale, Standard of care, Security (finance)

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross proceeds of approximately $11.1 million to RenovoRx, before deducting offering expenses.

Key Points: 
  • RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross proceeds of approximately $11.1 million to RenovoRx, before deducting offering expenses.
  • The proceeds from this financing, in addition to RenovoRx’s previously announced private placement on January 29, 2024 for gross proceeds of approximately $6.1 million, extend the Company’s cash runway into 2026.
  • The financing allows RenovoRx to advance its lead program, the pivotal Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer (LAPC), through the second interim readout and towards completion of the trial.
  • Investors will pay a purchase price of $1.4075 for each share and associated Series A Warrant and Series B Warrant, with such price being at the market for purposes of Nasdaq Stock Market rules.

Alethea Raises $20M in Series B Funding for Disinformation Mitigation

Retrieved on: 
Tuesday, April 9, 2024
GV, Organization, Data science, The New York Times, Acceleration, Intelligence, Risk, General partnership, SAN, Venture round, GRU, Social media, Research, Invisible ink, Fortune 500, Public sector, Series, Intel, Marketing, Engineering, Risk management

WASHINGTON and SAN FRANCISCO, April 9, 2024 /PRNewswire/ -- Alethea , the leading technology company in disinformation detection and mitigation, announced the close of a $20M Series B funding round led by GV , with participation from Ballistic Ventures , who led Alethea's Series A funding in 2022.

Key Points: 
  • WASHINGTON and SAN FRANCISCO, April 9, 2024 /PRNewswire/ -- Alethea , the leading technology company in disinformation detection and mitigation, announced the close of a $20M Series B funding round led by GV , with participation from Ballistic Ventures , who led Alethea's Series A funding in 2022.
  • Alethea is the leading technology company in disinformation detection and mitigation.
  • Alethea was represented by outside counsel WilmerHale in the Series B transaction.
  • Visit the Alethea careers page for more information on open positions across data science, product, engineering, finance, operations, and marketing and sales.

Milestone in the Artificial Intelligence Industry - AIXtreme announces IPO to enter Nasdaq

Retrieved on: 
Friday, March 15, 2024
Algorithm, Growth, Intelligence, Meta, Research, Nifedipine, Acquisition, Interview, IPO, Venture round, Prospectus, Decentralized finance, Ecosystem, USDT, NVIDIA, A100, Cryptocurrency

Birmingham, UK, March 15, 2024 (GLOBE NEWSWIRE) -- AIXtreme Ltd., a pioneering entity in the realm of artificial intelligence, proudly declared its submission of a prospectus to Nasdaq for final audit before IPO to enter Nasdaq.

Key Points: 
  • Birmingham, UK, March 15, 2024 (GLOBE NEWSWIRE) -- AIXtreme Ltd., a pioneering entity in the realm of artificial intelligence, proudly declared its submission of a prospectus to Nasdaq for final audit before IPO to enter Nasdaq.
  • This significant move signifies a crucial stride for AIXtreme towards establishing its presence on the global financial stage of Nasdaq.
  • The IPO to enter Nasdaq is poised to garner extensive attention and financial backing from global investors, thereby enhancing the company's brand influence and market competitiveness.
  • As AITAEX prepares for its IPO to enter Nasdaq, global investors are invited to partake in this innovative journey of merging technology and finance.

Solidion Technology, Inc. Announces Pricing of $3.85 Million Private Placement

Retrieved on: 
Thursday, March 14, 2024
Exercise, EF Hutton, Venture round, Winston & Strawn, Sale, Security (finance)

The closing of the private placement is expected to occur on March 14, 2024, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement.

Key Points: 
  • The closing of the private placement is expected to occur on March 14, 2024, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement.
  • In connection with the private placement, the Company will issue an aggregate of 5,133,332 units and pre-funded units.
  • The Company intends to use the net proceeds from the private placement primarily for general working capital and administrative purposes.
  • Benesch Friedlander Coplan & Aronoff LLP and Loeb & Loeb LLP are serving as counsel to the Company for the private placement.

Empathy Announces $47M Series B, Solidifying Its Position as a Leader in the Emerging Compassionate Economy

Retrieved on: 
Tuesday, March 12, 2024
Attention, Grief, Entrepreneurship, Allianz, Venture round, Mental health, Index Ventures, MetLife, Insurance, Life, Loss, Workplace, Family, Work

Empathy continues to set new standards for supporting families through grief and loss,” said Ron Gura, Co-Founder and CEO of Empathy.

Key Points: 
  • Empathy continues to set new standards for supporting families through grief and loss,” said Ron Gura, Co-Founder and CEO of Empathy.
  • “We are honored to provide help in a sustainable, scalable way by working with employers and insurance carriers to become the new standard for modern benefits.
  • The Series B funding will be used to expand Empathy’s services and cover new industries and regions nationwide.
  • “Empathy's approach to grief and loss support is defining the emerging compassionate economy, built around anticipating the needs of employees outside of work,” said Danny Rimer, Partner at Index Ventures.

Capstan Therapeutics Announces $175M Oversubscribed Series B Financing

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Polaris Partners, Cell, General partnership, Venture round, RNA, Messenger, Bristol Myers Squibb, MBA, Bayer, Therapy, OrbiMed, Immune system, Eli Lilly and Company, Series, Investment, Blood, Vaccine

Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing.

Key Points: 
  • Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing.
  • The Series B financing was led by RA Capital Management, with participation from new investors Forbion, Johnson & Johnson Innovation - JJDC, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments.
  • The proceeds from the Series B financing will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline.
  • “This Series B financing brings together an exceptional syndicate of investors that recognize the potential of Capstan’s in vivo CAR-T technology,” said Laura Shawver, Ph.D., President and Chief Executive Officer of Capstan.